Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma

Dimpy Koul, Ruijun Shen, Sherry Bergh, Xiaoyang Sheng, Shishir Shishodia, Tiffany A. Lafortune, Yiling Lu, John F. de Groot, Gordon Mills, W. K Alfred Yung

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Phosphatase and tensin 'homologue deleted on chromosome 10 (PTEN) and Akt are important regulators of the phosphatidylinositol 3-kinase (PI3K) pathway and thus are important to the regulation of a wide spectrum of tumor-related biological processes. Akt regulates several critical cellular functions, including cell cycle progression; cell migration, invasion, and survival; and angiogenesis. Decreased expression of PTEN and overexpression of the Akt proto-oncogene, which is located downstream of PI3K, have been shown in a variety of cancers, including glioblastoma. Novel small-molecule inhibitors of receptors and signaling pathways, including inhibitors of the PI3K pathway, have shown antitumor activity, but inhibitors of Akt have not been examined. In this study, we tested our hypothesis that the pharmacologic inhibition of Akt has an antiproliferative effect on gliomas. We showed that two newly developed Akt inhibitors, KP-372-1 and KP-372-2 (herein called KP-1 and KP-2), effectively inhibited the PI3K/Akt signaling cascade. KP-1 and KP-2 blocked both the basal and epidermal growth factor-induced phosphorylation of Akt Ser473 at 125 and 250 nmol/L, which, in turn, reduced the activation of intracellular downstream targets of Akt, including GSK-3β and p70s6k. Furthermore, the treatment of U87 and U251 glioma cells with 125 to 250 nmol/L KP-1 and KP2 for 48 hours inhibited cell growth by ∼50%. This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas.

Original languageEnglish (US)
Pages (from-to)637-644
Number of pages8
JournalMolecular Cancer Therapeutics
Volume5
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Glioblastoma
Glioma
Survival
70-kDa Ribosomal Protein S6 Kinases
Glycogen Synthase Kinase 3
Biological Phenomena
Chromosomes, Human, Pair 10
Proto-Oncogenes
Growth
Phosphoric Monoester Hydrolases
Epidermal Growth Factor
Cell Movement
Neoplasms
Cell Survival
Cell Cycle
Phosphorylation
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Koul, D., Shen, R., Bergh, S., Sheng, X., Shishodia, S., Lafortune, T. A., ... Yung, W. K. A. (2006). Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Molecular Cancer Therapeutics, 5(3), 637-644. https://doi.org/10.1158/1535-7163.MCT-05-0453

Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. / Koul, Dimpy; Shen, Ruijun; Bergh, Sherry; Sheng, Xiaoyang; Shishodia, Shishir; Lafortune, Tiffany A.; Lu, Yiling; de Groot, John F.; Mills, Gordon; Yung, W. K Alfred.

In: Molecular Cancer Therapeutics, Vol. 5, No. 3, 01.03.2006, p. 637-644.

Research output: Contribution to journalArticle

Koul, D, Shen, R, Bergh, S, Sheng, X, Shishodia, S, Lafortune, TA, Lu, Y, de Groot, JF, Mills, G & Yung, WKA 2006, 'Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma', Molecular Cancer Therapeutics, vol. 5, no. 3, pp. 637-644. https://doi.org/10.1158/1535-7163.MCT-05-0453
Koul, Dimpy ; Shen, Ruijun ; Bergh, Sherry ; Sheng, Xiaoyang ; Shishodia, Shishir ; Lafortune, Tiffany A. ; Lu, Yiling ; de Groot, John F. ; Mills, Gordon ; Yung, W. K Alfred. / Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. In: Molecular Cancer Therapeutics. 2006 ; Vol. 5, No. 3. pp. 637-644.
@article{162059689b884aa99aea5ea846965805,
title = "Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma",
abstract = "Phosphatase and tensin 'homologue deleted on chromosome 10 (PTEN) and Akt are important regulators of the phosphatidylinositol 3-kinase (PI3K) pathway and thus are important to the regulation of a wide spectrum of tumor-related biological processes. Akt regulates several critical cellular functions, including cell cycle progression; cell migration, invasion, and survival; and angiogenesis. Decreased expression of PTEN and overexpression of the Akt proto-oncogene, which is located downstream of PI3K, have been shown in a variety of cancers, including glioblastoma. Novel small-molecule inhibitors of receptors and signaling pathways, including inhibitors of the PI3K pathway, have shown antitumor activity, but inhibitors of Akt have not been examined. In this study, we tested our hypothesis that the pharmacologic inhibition of Akt has an antiproliferative effect on gliomas. We showed that two newly developed Akt inhibitors, KP-372-1 and KP-372-2 (herein called KP-1 and KP-2), effectively inhibited the PI3K/Akt signaling cascade. KP-1 and KP-2 blocked both the basal and epidermal growth factor-induced phosphorylation of Akt Ser473 at 125 and 250 nmol/L, which, in turn, reduced the activation of intracellular downstream targets of Akt, including GSK-3β and p70s6k. Furthermore, the treatment of U87 and U251 glioma cells with 125 to 250 nmol/L KP-1 and KP2 for 48 hours inhibited cell growth by ∼50{\%}. This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas.",
author = "Dimpy Koul and Ruijun Shen and Sherry Bergh and Xiaoyang Sheng and Shishir Shishodia and Lafortune, {Tiffany A.} and Yiling Lu and {de Groot}, {John F.} and Gordon Mills and Yung, {W. K Alfred}",
year = "2006",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-05-0453",
language = "English (US)",
volume = "5",
pages = "637--644",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma

AU - Koul, Dimpy

AU - Shen, Ruijun

AU - Bergh, Sherry

AU - Sheng, Xiaoyang

AU - Shishodia, Shishir

AU - Lafortune, Tiffany A.

AU - Lu, Yiling

AU - de Groot, John F.

AU - Mills, Gordon

AU - Yung, W. K Alfred

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Phosphatase and tensin 'homologue deleted on chromosome 10 (PTEN) and Akt are important regulators of the phosphatidylinositol 3-kinase (PI3K) pathway and thus are important to the regulation of a wide spectrum of tumor-related biological processes. Akt regulates several critical cellular functions, including cell cycle progression; cell migration, invasion, and survival; and angiogenesis. Decreased expression of PTEN and overexpression of the Akt proto-oncogene, which is located downstream of PI3K, have been shown in a variety of cancers, including glioblastoma. Novel small-molecule inhibitors of receptors and signaling pathways, including inhibitors of the PI3K pathway, have shown antitumor activity, but inhibitors of Akt have not been examined. In this study, we tested our hypothesis that the pharmacologic inhibition of Akt has an antiproliferative effect on gliomas. We showed that two newly developed Akt inhibitors, KP-372-1 and KP-372-2 (herein called KP-1 and KP-2), effectively inhibited the PI3K/Akt signaling cascade. KP-1 and KP-2 blocked both the basal and epidermal growth factor-induced phosphorylation of Akt Ser473 at 125 and 250 nmol/L, which, in turn, reduced the activation of intracellular downstream targets of Akt, including GSK-3β and p70s6k. Furthermore, the treatment of U87 and U251 glioma cells with 125 to 250 nmol/L KP-1 and KP2 for 48 hours inhibited cell growth by ∼50%. This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas.

AB - Phosphatase and tensin 'homologue deleted on chromosome 10 (PTEN) and Akt are important regulators of the phosphatidylinositol 3-kinase (PI3K) pathway and thus are important to the regulation of a wide spectrum of tumor-related biological processes. Akt regulates several critical cellular functions, including cell cycle progression; cell migration, invasion, and survival; and angiogenesis. Decreased expression of PTEN and overexpression of the Akt proto-oncogene, which is located downstream of PI3K, have been shown in a variety of cancers, including glioblastoma. Novel small-molecule inhibitors of receptors and signaling pathways, including inhibitors of the PI3K pathway, have shown antitumor activity, but inhibitors of Akt have not been examined. In this study, we tested our hypothesis that the pharmacologic inhibition of Akt has an antiproliferative effect on gliomas. We showed that two newly developed Akt inhibitors, KP-372-1 and KP-372-2 (herein called KP-1 and KP-2), effectively inhibited the PI3K/Akt signaling cascade. KP-1 and KP-2 blocked both the basal and epidermal growth factor-induced phosphorylation of Akt Ser473 at 125 and 250 nmol/L, which, in turn, reduced the activation of intracellular downstream targets of Akt, including GSK-3β and p70s6k. Furthermore, the treatment of U87 and U251 glioma cells with 125 to 250 nmol/L KP-1 and KP2 for 48 hours inhibited cell growth by ∼50%. This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas.

UR - http://www.scopus.com/inward/record.url?scp=33645473862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645473862&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0453

DO - 10.1158/1535-7163.MCT-05-0453

M3 - Article

VL - 5

SP - 637

EP - 644

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -